CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Selumetinib Sulfate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02839720
NCT02839720Phase 2Completed
CompareCT.gov

Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)

National Cancer Institute (NCI)·interventional·Posted Jul 21, 2016·Updated Dec 6, 2023

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Selumetinib Sulfate for Cutaneous Neurofibroma and 2 related conditions. Completed, enrolled 11 participants across 2 sites.

Detailed Summary

This pilot phase II trial studies how well selumetinib works in treating patients with neurofibromatosis type 1 and cutaneous neurofibromas. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous Neurofibroma, Neurofibromatosis Type 1, Optic Nerve Glioma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 21, 2016
Enrollment StartAug 26, 2017
Primary CompletionNov 5, 2022
Study CompletionAug 31, 2023
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 9.9 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Selumetinib Sulfatedrug

Given PO